Artiva Biotherapeutics, Inc. ARTV Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s additional paid-in capital?
- Artiva Biotherapeutics, Inc. (ARTV) reported additional paid-in capital of $441.93M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Artiva Biotherapeutics, Inc.'s additional paid-in capital increased by 1.4% year-over-year, from $435.78M to $441.93M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s additional paid-in capital has grown at a 381.6% compound annual growth rate (CAGR), from $18.99M to $440.41M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.